A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

To join this study, you must have advanced non-small cell lung cancer that has spread and has a specific genetic change called a 'homozygous MTAP deletion' in your tumour. Your cancer also needs to have worsened after you've had other treatments. You must be at least 18 years old and generally well enough to take part, with a good level of physical activity.

There are also some reasons why you might not be able to join. For example, if you have active brain tumours, certain tummy or bowel conditions that might affect how you absorb medicines, or if you've already had a similar type of experimental drug (PRMT5 or MAT2A inhibitor). Your study doctor will check if you fit all the criteria.

If you join this study, you would be taking an investigational medication, Navlimetostat, which is given as tablets you swallow. You would have regular visits to the hospital or clinic for assessments. These will include blood tests, scans (like CT scans) to check your cancer, and check-ups with the study team to monitor your health and any side effects. You'll need to be able to swallow tablets whole. The total duration of your participation would depend on how you respond to the treatment and the study plan, but you will be monitored regularly throughout.